Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

► Adults ≥40 years of age are commonly hypo-responsive to licensed HBV vaccines. ► HBsAg-1018 ISS elicits earlier, higher and longer lasting antibody than Engerix-B. ► 2 doses of HBsAg-1018 ISS provides superior protection over 3 doses of Engerix-B. ► HBsAg-1018 ISS was well tolerated with a similar safety profile as Engerix-B. ► HBsAg-1018 ISS may be more effective in hypo-responsive populations.